From the Guardian today: Bdsi not being taken seriously enough by RB and the global investors. What's one to do... hedge! Well, perhaps.Didn't mention the tablets either...
Reckitt Benckiser has neither issued a trading update nor seen its shares go ex-dividend.
But it is one of the biggest fallers in the FTSE 100 after analysts at UBS slashed their rating on the Cillit Bang and pharmaceuticals group. Reckitt, which is considering a disposal of its drugs business best know for heroin treatment Suboxone, is down 51p at £48.14 as UBS moved from buy to sell. The bank said:
We believe Reckitt's current valuation implies a much greater valuation for the pharmaceutical division than is likely to be released if the management opts for disposal, and the risks to [the division's] profits after 2016 from the threat of a generic film buprenorphine are being overlooked.
Who knows! The whole space is unusually "political" . If the FDA has only old generation Visian safety data to go on they might pull out the cataract red card out as a reason not to encourage more use of a posterior lens. The docs themselves have reported very low cataract formation with newer v4 lenses...0.05% said the Argentine. Centraflow is supposed to protect the crystalline lens, too. Barry sounded very confident on the last call... and was talking as though the whole mindset at the FDA had changed such that Centraflow would be a cakewalk!
The in-between customer "CASI" is a small player compared to Swisslog... Adept's earlier partner. But this kind of news should put a little heat on the bigger guys in the space. Swisslog has lost its way in recent years -strong franc? anyway ceo and board changes have not helped. The Siemens's spin-off Dematic is a well-funded gorilla in this space with some of their own "robots" and has been eating Swisslog's lunch. Now, if we could get business with those kinds of big players that would be something else. This team has played down the healthcare market, but that is where we could see even larger value creation.
Hi... I saw ads for this... looks to solve most of the LASIK problems. Especially dry eye... but then in one study they found the overall complications to be the same. Vision correction is same as LASIK? But they are a 500k usd investment + service + maintenance + training + bulky... so space. Like you say: one needed. The newer Visians with centerflow seem to solve the two chair problem (often 2 site) without added investment or space for the equipment. They say they can do the op in less than 15 min, less than the time need to just program the laser. Pre-loaded takes 2 min off that too!
As for cost, well the visian is cheap to start with... they indicate 80 usd per lens ex-factory. So, if the non-toric patient cost is 2500 or so there is a lot of profit motivation for all parties! For the femto laser I guess the annual fixed cost is some 150K, so a lot of patients needed. On the other hand they are versatile and can be used for a variety of other ops not just vision correction.
All-time highs have stuck.. for now. IPO investors now have a small return from their 2 decade wait, which is nice. Looking around the scene, an elgx-kind of p/s valuation still leaves another 70% to go though!
Adding the options outstanding, we basically passed the billion dollar market cap last few days: champagne!
At least 1 of my predictions came true. After 10 depends who wants in... volume says active funds are buying in. No million sellers at 4 as there were a few months ago,, and I doubt the co. is buying own shares despite the volume.
Read the 10Q P/Ls for facts... the cc talk can be confusing. I think the Abbivie deal is a good one for Sucampo but it's not THAT good as some post! Plus Sucampo has regulatory costs from Japan sales it would not have with a royalty agreement...
It will, if they keep it up. so far the prs have been in-line with the deals talked about in the cc. Click need to re-make itself and it takes time. Still, its difficult to be brick and cloud at the same time. "Real" cloud businesses are growing at 50+%, implying they do not sell by going door-to-door, customers seek them out over the net. I suspect re-sellers like SAP slow the sales process down as well, although without them there may be no deal at all...
Incorrect. Sucampo has a 40% gross margin on sales to AbbVie. If Abb takes a 50% margin on its sales to pharmacy/payer, that's an effective 20% share of the sales to the op profit line. Abbi might take a lot less when it starts up the biz to grab "share". So it's basically a wash with the royalty on Takeda biz in USA. Does look nicer though for the valuation.
Data from 3 studies at AHA yesterday. Surprising results overall. Tbio's multiple gene test would not likely fare any better. Still not been much joy for tbio lately anyway... and costs now outsourced.
An outsider cannot know whether this is true or not, but they are issues that are easily fixed, if management changes ... Not that feedback is THAT positive for most companies, eg TOA. It's amazing what a clean sweep can do in a company, eg Adept or Datawatch... exisitng managment can benefit more through their asset-holding than their actions!
Pros – The people that work below the director level are qualified hard workers that strive to do their jobs correctly even when directed otherwise by the management team. These folks were a pleasure to work with.
Cons – The management team lacks too many required skills and qualities to list. Suffice it to say that the company will remain growth stagnant until major high level change occurs.
Advice to Senior Management – Treat existing clients as well as you treat new clients so that you can retain your client base, which trends negatively on a yearly basis. Also, do something about the corporate culture as it is a very dismal work environment
Yep correction in order: calls are on the site... they are just invisible to a firefox user! Transcribers have always had problems understanding Zack... not that he gives anything away!
If... or when?... they get back to earlier revenues, they will show a profit even if higher r&D amoritization hits. However, time is running out... only 200K left to borrow from Zack and no bank will enter on his terms. He can keep it going, but will he? and at what price?? Often, Q4 has given them some good license revenue upfront.. this seems to be left to Europe now as sales to NA are dismal (hopefully reflecting saas). Voice call replay is never on site as promised... is that a sign, too?
We should have got shares in the new entity and also realized the immediate synergies. I expect to near 100 on the guidance, but the easy part has been made! Still insiders have sold 6m shares in last 6 months... why? Just Cosmo? Price has barely risen in 6 m and down from peak... shorting? or the fact that some of the meds go generic in a few years...
I heard that, too. They should not have that kind of cost though, and cannot afford it! A lot of the stuff they make or services they offer now has sales outsourced. They shoudl be left with marketing, clinical support, meetings etc, only... ans 1 guy for scoliscore! The admin should be 600k or so.. depending what exactly is in there and not in the cogs. So I just don't get 4m in sales expense some 4m in gross margin (on a good day). No-one wants to sell today?
Quick look at the b/s tells us that they can't suffer too many loss making quarters! If it is true they took a 3m writedown in the quarter as well as other restructuring expenses, we might see ongoing sga down to 3.5 m? together with r&d of .6 that means sales of close to 8 m a quarter are need for cash-flow break even. They have done it before, a year ago, but that included medicare sales... which turned out to be charity. Luckily q4 is a strong one for tools and equipment - normally. Listening to this Kinnon guy indicates he is the exact opposite of Tuttle! A scouser? from a polytechnic, rather than cool-california craig. Just what our doctor ordered.
Well expressed! You may well know, but "they" seem to be have found a way to improve the laser treatment. Iridex has come back from the dead - as an investment - on the back of micropulse. They have nice pictures, too! There is a big enough market for all approaches, after all.
It's more co-incidence than a thought out strategy but it's a hedge against these drugs not panning out... It is silly to have a 10-fold return on some irix shares and a negative return from lptn, considering the potential in Lpath - but that's what absence of dilution can achieve. If isonnep works as a monotherapy it would of course be a paradigm shift.
Maybe explains the spike in sp in October! So, market for their product exists, question is: what is the real growth rate in the medium term, the 300% or the 12%? Putting Mike's comments on Google the other way around, it should make you think that why would google buy this ROD service rather than offer it themselves - by copying the idea or buying the company!